Amundi’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $28.4M | Sell |
219,195
-11,992
| -5% | -$1.55M | 0.01% | 650 |
|
|
2025
Q1 | $23.8M | Sell |
231,187
-30,673
| -12% | -$3.16M | 0.01% | 683 |
|
|
2024
Q4 | $36.3M | Sell |
261,860
-394,835
| -60% | -$54.8M | 0.01% | 624 |
|
|
2024
Q3 | $73.3M | Buy |
656,695
+265,382
| +68% | +$29.6M | 0.03% | 471 |
|
|
2024
Q2 | $54.1M | Buy |
391,313
+29,641
| +8% | +$4.1M | 0.02% | 503 |
|
|
2024
Q1 | $47.9M | Buy |
361,672
+21,458
| +6% | +$2.84M | 0.02% | 530 |
|
|
2023
Q4 | $45.5M | Buy |
340,214
+34,820
| +11% | +$4.66M | 0.02% | 546 |
|
|
2023
Q3 | $34.5M | Sell |
305,394
-884,632
| -74% | -$99.8M | 0.02% | 586 |
|
|
2023
Q2 | $112M | Sell |
1,190,026
-31,815
| -3% | -$3.01M | 0.06% | 333 |
|
|
2023
Q1 | $125M | Buy |
1,221,841
+298,475
| +32% | +$30.5M | 0.07% | 299 |
|
|
2022
Q4 | $102M | Buy |
923,366
+106,554
| +13% | +$11.8M | 0.06% | 342 |
|
|
2022
Q3 | $88.7M | Buy |
816,812
+751,542
| +1,151% | +$81.7M | 0.05% | 364 |
|
|
2022
Q2 | $6.15M | Sell |
65,270
-581
| -0.9% | -$54.8K | ﹤0.01% | 876 |
|
|
2022
Q1 | $6.49M | Sell |
65,851
-73,571
| -53% | -$7.25M | ﹤0.01% | 916 |
|
|
2021
Q4 | $11M | Buy |
139,422
+1,527
| +1% | +$121K | 0.01% | 816 |
|
|
2021
Q3 | $13.2M | Buy |
137,895
+16,109
| +13% | +$1.55M | 0.01% | 773 |
|
|
2021
Q2 | $11.9M | Buy |
+121,786
| New | +$11.9M | 0.01% | 798 |
|